CAJ | 학술논문

目的：探究与分析在老年性痴呆的治疗过程中，以美金刚代替卡巴拉汀治疗的远期临床疗效和安全性评价。方法选了本院自2013年12月至2014年12月收治的100例住院1年的老年性痴呆患者，以随机对照表法分为A、B两组，每组50例。 A组患者继续给予卡巴拉汀治疗；B组患者给予美金刚替代治疗，以简易智能状态检查量表（ mini mental state examination，MMSE）、AD评估量表认知分量表（ ADAS-cog）、日常生活活动能力量表（ ADL）、总体衰退量表（ GDS）等评分作为主要评价指标，比较两组患者在治疗前与治疗2个月、4个月、6个月、8个月、10个月和12个月后的认知能力、精神状况、日常生活能力的改善情况。观察记录B组患者在治疗过程中的不适现象以进行安全性评价。结果①B组患者简易智能状态检查量表、AD评估量表认知分量表、日常生活活动能力量表（ ADL）、总体衰退量表（ GDS）在替代治疗后第2个月、4个月、6个月、8个月、10个月和12个月优于A组患者，差异有统计学意义（ P＜0.05）。②B组患者在治疗过程中出现的不适现象少且轻微，安全性高。结论美金刚治疗老年性痴呆的远期疗效良好，安全性有保证，是治疗老年性痴呆的最佳方案。
목적：탐구여분석재노년성치태적치료과정중，이미금강대체잡파랍정치료적원기림상료효화안전성평개。방법선료본원자2013년12월지2014년12월수치적100례주원1년적노년성치태환자，이수궤대조표법분위A、B량조，매조50례。 A조환자계속급여잡파랍정치료；B조환자급여미금강체대치료，이간역지능상태검사량표（ mini mental state examination，MMSE）、AD평고량표인지분량표（ ADAS-cog）、일상생활활동능역량표（ ADL）、총체쇠퇴량표（ GDS）등평분작위주요평개지표，비교량조환자재치료전여치료2개월、4개월、6개월、8개월、10개월화12개월후적인지능력、정신상황、일상생활능력적개선정황。관찰기록B조환자재치료과정중적불괄현상이진행안전성평개。결과①B조환자간역지능상태검사량표、AD평고량표인지분량표、일상생활활동능역량표（ ADL）、총체쇠퇴량표（ GDS）재체대치료후제2개월、4개월、6개월、8개월、10개월화12개월우우A조환자，차이유통계학의의（ P＜0.05）。②B조환자재치료과정중출현적불괄현상소차경미，안전성고。결론미금강치료노년성치태적원기료효량호，안전성유보증，시치료노년성치태적최가방안。
Objectives To explore and analyze the process in the treatment of senile dementia, the long term clinical evaluation of the efficacy and safety of memantine treatment to replace the Kabbala ting.Methods Selected in our hospital from 2013 Decem-ber to 2014 December were 100 cases of hospitalized patients with senile dementia in 1 years, in a random control table method is divided into A, B two groups, 50 cases in each group.A group of patients continue to give Kabbala Ting treatment;group B patients were given replacement therapy with memantine, MMSE ( mini mental state examination, MMSE) , AD assessment scale cognitive subscale ( ADAS-cog) , activity of daily living scale ( ADL) and total body depression scale ( GDS) score as the main evaluation in-dex, improvement in 2, 4, 6, 8, 10 and 12 months after the cognitive ability, spirit condition, ability of daily life in patients of 2 groups were compared before treatment and treatment.Observe and record the patients in the B group in the course of treatment the discomfort for safety evaluation.Results In group B patients, MMSE, AD assessment scale cognitive subscale, activities of daily living scale (ADL), Global Deterioration Scale (GDS) in the replacement therapy after second, 4, 6, 8, 10 and 12 months than patients in the A group, the difference has statistical significance ( P<0.05).The B group patient discomfort phenomenon appea-ring in the process of treatment with few and mild, high safety.Conclusions The long-term efficacy of memantine in the treatment of Alzheimer’ s disease is good, safety has safeguard, is the best treatment of senile dementia.